Država: Kanada
Jezik: angleščina
Source: Health Canada
BENDAMUSTINE HYDROCHLORIDE
NATCO PHARMA (CANADA) INC
L01AA09
BENDAMUSTINE
25MG
POWDER FOR SOLUTION
BENDAMUSTINE HYDROCHLORIDE 25MG
INTRAVENOUS
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0153268001; AHFS:
APPROVED
2021-02-25
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR NAT-BENDAMUSTINE (BENDAMUSTINE HYDROCHLORIDE FOR INJECTION) Lyophilized Powder for Injection, 25 mg / vial and 100 mg / vial, for intravenous infusion USP Antineoplastic agent Natco Pharma (Canada) Inc. 2000 Argentia Road, Plaza 1, Suite 200 Mississauga, Ontario L5N 1P7 Date of Initial Authorization: MAR 04, 2020 Date of Revision: MAY 05, 2023 Submission Control Number: 273010 _ _ _NAT-BENDAMUSTINE (bendamustine hydrochloride) _ _Page 2 of 41_ RECENT MAJOR LABEL CHANGES 1 Indications, 1.1 Pediatrics 05/2022 7 Warnings and Precautions, Carcinogenesis and Mutagenesis 05/2022 7 Warnings and Precautions, Immune 05/2022 7 Warnings and Precautions, Monitoring and Laboratory Tests 05/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics......................................................................................................... 4 1.2 Geriatrics ......................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 4 4 DOSAGE AND ADMINISTRATION................................................................................. 5 4.1 Dosing Considerations...................................................................................... 5 Preberite celoten dokument